Articles

Advanced PD is complicated by the loss of non-dopaminergic neurones, resulting in symptoms that are largely unresponsive to dopaminergic therapy....

In this study from Denmark, 12 PD patients were assessed for Duodopa pump therapy. Each patient had a permanent percutaneous endoscopic gastrostomy...

The minimum time to symptom improvement after initiation of treatment with ropinirole prolonged release (ropinirole-PR; 2-24 mg/day) versus placebo...

Maximum treatment duration was 10.7 years. Fifty-two patients were treated for 1 year or longer. The adverse effect profile of levodopa/carbidopa...

Drug delivery systems that have been instituted for the delivery of l-DOPA include immediate-release formulations, liquid formulations, dispersible...

Various levodopa-based strategies are currently available that aim to control motor complications (wearing-off and dyskinesia) in PD, including dose...

Pardoprunox is a novel, partial dopamine receptor agonist. In the current randomized, placebo-controlled study, the authors evaluated its safety and...

Although levodopa is the cornerstone treatment for PD, its short half-life limits the usefulness of the drug in later stages of the disease. Duodenal...

Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits MAO-B more potently than selegiline does, and...